AIM ImmunoTech Secures Crucial Patent for Cancer Innovation
AIM ImmunoTech Inc. (NYSE: AIM) has reached a significant milestone by securing a patent from the Japan Patent Office. This patent protects the unique use of Ampligen (Rintatolimod) when combined with checkpoint inhibitors, paving the way for innovative cancer treatment strategies.
The Importance of the Patent
By obtaining this patent, AIM strengthens its intellectual property portfolio, particularly in one of the largest pharmaceutical markets in the world. The granted patent in Japan does not expire until December 20, 2039, enhancing the company's ability to protect and monetize its unique therapies.
Commitment to Global Protection and Development
AIM is dedicated to expanding its reach through international market protection. This patent not only reinforces AIM's position in oncology but also opens doors for potential licensing deals and collaborations that could drive long-term growth.
Combining Ampligen with Checkpoint Inhibitors
The claims of the patent encompass multiple cancer types, which indicates AIM’s strategic move to target various challenging cancers. These include pancreatic cancer, colorectal cancer, melanoma, and triple-negative breast cancer among others. This broad coverage significantly enhances the value of the patent, allowing AIM to explore diverse applications of its therapies.
Prior Patents and Future Directions
In addition to the new patent in Japan, AIM holds patents in the U.S. and the Netherlands, further solidifying its commitment to intellectual property in oncology. With the U.S. patent set to expire on August 9, 2039, and the Netherlands patent set for December 19, 2039, AIM's strategic planning positions it favorably within the competitive landscape of cancer therapies.
Clinical Developments and Collaborations
The combination therapy using Ampligen is designed to work synergistically with checkpoint inhibitors, potentially revolutionizing treatment for cancers resistant to conventional therapies. Current collaborations, such as the ongoing Phase 2 clinical trial with AstraZeneca for metastatic pancreatic cancer, showcase promising early results, indicating enhanced patient outcomes.
Future Clinical Studies
AIM continues to expand its research through collaborations with leading pharmaceutical companies. A Phase 2 study involving Keytruda in advanced recurrent ovarian cancer has recently been completed, with final data expected soon.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an innovative biopharma company that focuses on developing therapies for cancer, viral diseases, and immune disorders. With its flagship product, Ampligen, currently in clinical trials, AIM aims to address significant gaps in treatment for various cancers and improve patient outcomes globally.
Contact Information
For more information, interested parties can reach out to:
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
Frequently Asked Questions
What is Ampligen?
Ampligen is AIM ImmunoTech’s investigational drug used in treating certain cancers and viral diseases. It acts as an immune modulator.
How does the new patent benefit AIM?
It provides exclusivity for the combination of Ampligen with checkpoint inhibitors, enhancing the company’s competitive edge in oncology.
What cancer types are targeted by this patent?
The patent covers several cancer types including pancreatic, colorectal, and breast cancers, among others.
Where else does AIM hold patents?
AIM holds patents in the U.S. and the Netherlands, ensuring robust protection for its therapies in multiple markets.
What partnerships is AIM involved in?
AIM is currently collaborating with AstraZeneca and Merck for trials involving Ampligen in combination with their checkpoint inhibitors.
